Novartis
NEWS
Some of the best medicines happen by accident. Will someone one day write the same of Novartis’s branaplam in correlation with Huntington’s disease?
It was a busy week for clinical trial announcements. Here’s a look.
Genentech shared new data from its SUNFISH study evaluating the use of Evrysdi for SMA people ages 2 to 25 years diagnosed with Type 2 or Type 3 spinal muscular atrophy.
More pharmaceutical companies are joining to put economic pressure on Russia by suspending some or all operations within that country following the invasion of Ukraine.
Novartis released new data Monday from its Phase III SPR1NT trial that reinforces the benefits of Zolgensma.
Bancel reaped the rewards of SpikeVax’s success, but the Boston Business Journal noted that annual compensation for Moderna’s median employee plunged 16%.
Voyager has partnered with Novartis for the latter to use the gene therapy company’s capsid discovery platform to create new treatments for three undisclosed CNS targets.
A new market research report by InsightAce Analytic projects the immuno-oncology or cancer immunotherapy market will hit $34.69 billion by 2030.
Silence Therapeutics, Totus Medicines and Poseida Therapeutics all adjust as they welcome new members to their leadership teams.
JOBS
IN THE PRESS